1AD.AX AdAlta Limited ASX down 28% on close 21 Jan 2026: clinical readout risk
The 1AD.AX stock fell sharply at market close on 21 Jan 2026, sliding 28.57% to A$0.005 on heavy volume of 11,005,191 shares as investors reacted to clinical timing and funding uncertainty. This sell‑off makes 1AD.AX one of today’s top losers on the ASX healthcare list. The move followed no company release but reflects stretched valuation, negative EPS of -0.01, and a year low near A$0.002, increasing near‑term volatility for holders and traders in the Australian biotechnology sector.
Price action and immediate drivers for 1AD.AX stock
Today’s close at A$0.005 represents a 28.57% fall from the previous close of A$0.007 and follows an intraday range A$0.005–A$0.006. Trading volume of 11,005,191 was ~1.36x the average, signalling forced selling or active repositioning around the AD‑214 clinical timetable.
Financial snapshot and valuation for 1AD.AX stock
AdAlta Limited (1AD.AX) shows a market capitalisation of A$783,356.00 with 130,559,400 shares outstanding and EPS of -0.01. Key ratios point to early‑stage biotech stress: PE is -0.60, price to sales 1.16, and cash per share A$0.00946, implying limited runway without new funding or milestone receipts.
Clinical programme and news flow impacting 1AD.AX stock
AdAlta’s lead candidate AD‑214 is in Phase I for idiopathic pulmonary fibrosis; clinical readouts and partner announcements are primary catalysts. There is no new earnings or regulatory release today, so the price change reflects investor positioning ahead of expected updates and the March earnings announcement window.
Technicals, liquidity and trading context for 1AD.AX stock
Technically, the 50‑day average is A$0.00394 and the 200‑day average is A$0.00329, both below today’s price, indicating the stock remains near long‑term lows. On‑book indicators show RSI ~50.75 and a high MFI of 81.91, suggesting short‑term overbought flows reversed quickly to heavy selling.
Meyka AI grade and forecast for 1AD.AX stock
Meyka AI rates 1AD.AX with a score out of 100: 67.53 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects A$0.01 over the next month, implying an ~100.00% upside from the current A$0.005. Forecasts are model‑based projections and not guarantees.
Risks and potential catalysts for 1AD.AX stock
Primary risks include trial setbacks, dilution from capital raises, and limited cash reserves; debt and operating cash flow metrics show stress for a small biotech. Potential catalysts are positive Phase I data, GE Healthcare collaboration milestones, or licensing deals, any of which could drive re‑rating in the ASX healthcare context.
Final Thoughts
1AD.AX stock closed the ASX session on 21 Jan 2026 at A$0.005, down 28.57%, as investors re‑price clinical and funding risk in AdAlta Limited. The company’s fundamentals show small market capitalisation A$783,356.00, negative EPS -0.01, and modest cash per share A$0.00946, which together heighten sensitivity to milestone news or capital events. Meyka AI’s model projects a near‑term target of A$0.01, implying ~100.00% upside versus the current price, but that projection is model‑based and not a guarantee. Given today’s top‑loser move, traders should expect elevated volatility and watch for any formal AD‑214 readouts or capital‑raising announcements. Long‑term investors should weigh the biotech sector backdrop, AdAlta’s partnership pipeline, and the company’s cash runway before altering position size. Meyka AI, our AI‑powered market analysis platform, will continue to track updates and adjust forecasts as new data arrive.
FAQs
Why did 1AD.AX stock fall today?
1AD.AX stock fell due to heavy selling ahead of clinical and funding uncertainty; volume spiked to 11,005,191 shares and the stock closed at A$0.005, reflecting re‑pricing of near‑term risk.
What is Meyka AI’s short‑term forecast for 1AD.AX stock?
Meyka AI’s forecast model projects A$0.01 over the next month for 1AD.AX stock, implying about 100.00% upside from A$0.005. Forecasts are model‑based projections and not guarantees.
What are the key risks for investors in 1AD.AX stock?
Key risks include clinical trial setbacks, dilution from capital raises, limited cash per share A$0.00946, and small market cap A$783,356.00 that increases volatility and liquidity risk for 1AD.AX stock.
Where can I find official company information on 1AD.AX stock?
Company disclosures and programme details are on AdAlta’s website and social channels. See company site AdAlta Limited and the company Twitter AdAlta for updates.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
